Quarter Period Consolidated Statement Of Comprehensive Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7356776

Concept 2023-04-01 to
2023-12-31
2022-04-01 to
2022-12-31
Quarter period consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
6,458,000,000 JPY
4,183,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
-131,000,000 JPY
858,000,000 JPY
Remeasurements of defined benefit plans, net of tax
-23,000,000 JPY
20,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
285,000,000 JPY
477,000,000 JPY
Other comprehensive income
130,000,000 JPY
1,355,000,000 JPY
Comprehensive income
6,588,000,000 JPY
5,538,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
6,588,000,000 JPY
5,538,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.